Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Dunad Therapeutics Enters Strategic Collaboration with Novartis to Develop Next-generation Oral Targeted Protein Degrader Therapies
Dunad Therapeutics (“Dunad”), a biopharmaceutical company focusing on the development of next-generation targeted protein degradation […]
Novartis Awarded Promising Innovative Medicine Designation for Targeted Radioligand Theragnostics in Prostate Cancer
Novartis today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Promising […]
NHS Announces Deal for Life Changing Sickle Cell Treatment
The first treatment for sickle cell disease in over 20 years will be rolled out […]
Novartis Acquires Arctos Medical, Expanding Optogenetics Portfolio to Bring Gene Therapies to Patients with Severe Vision Loss
Novartis today announced that it has acquired Arctos Medical, adding a pre-clinical optogenetics-based AAV gene […]
World-first Agreement Between Novartis and the NHS Enables Broad and Rapid Access to First-in-class Cholesterol-lowering Medicine Leqvio® ▼(inclisiran)
Novartis has reached a commercial agreement with the NHS in England as part of a […]
Kesimpta® (Ofatumumab) Data Show Long-term Preservation of IgG/IgM Levels and no Increased Risk of Serious Infections in People Living with Multiple Sclerosis
Today, Novartis disclosed new data showing mean IgG and IgM levels remain unchanged in adults […]
Novartis Announces Iptacopan Met Phase II Study Primary Endpoint in Rare Kidney Disease IgA Nephropathy (IgAN)
Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, […]
Novartis Presents Positive Phase III Results From JUNIPERA Study Supporting Cosentyx® as a Potential Treatment in a JIA Population at EULAR 2021
Novartis, a leader in rheumatology and immuno-dermatology, today announced 2-year positive results from the Phase […]
Novartis and Molecular Partners Announce Start of EMPATHY Clinical Trial for Ensovibep for the Treatment of COVID-19
Novartis and Molecular Partners announced today the start of the clinical trial EMPATHY, a Phase […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more